PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
59.45%
Revenue growth of 59.45% vs. zero growth in Drug Manufacturers - Specialty & Generic. Walter Schloss might still want to see if it can translate into profits.
-53.84%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-103.69%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is -0.00%. Seth Klarman would check if external or internal factors caused the decline.
-103.69%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
153.01%
Net income growth of 153.01% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see potential if moderate gains can keep rising.
141.84%
EPS growth of 141.84% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
141.84%
Diluted EPS growth of 141.84% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
8.51%
Share change of 8.51% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if the modest difference matters long-term.
8.22%
Diluted share change of 8.22% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
89.50%
OCF growth of 89.50% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
24.16%
FCF growth of 24.16% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.82%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.67%. Joel Greenblatt might see a short-term competitive advantage at play.
-109.34%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-273.64%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-202.53%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
3051.78%
Net income/share CAGR of 3051.78% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
11082.24%
Net income/share CAGR of 11082.24% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
2188.69%
3Y net income/share CAGR of 2188.69% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a small advantage that can be scaled further.
3410.56%
Equity/share CAGR of 3410.56% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
16854.11%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 5.93%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
448.58%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 9.66%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.98%
AR growth of 7.98% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
13.55%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
26.26%
Asset growth of 26.26% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
10.83%
BV/share growth of 10.83% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-3.57%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
128.48%
R&D growth of 128.48% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
15.04%
SG&A growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.